 CAMBRIDGE, Mass.--BUSINESS WIRE--Acceleron Pharma Inc. Nasdaq:XLRN, a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced net sales of REBLOZYL luspatercept-aamt as reported by its global collaborator, Bristol Myers Squibb, were approximately 112 million for the first quarter ended March 31, 2021. Acceleron expects to report royalty revenue of approximately 22.4 